Inhibrx Biosciences (INBX) Cash & Equivalents (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Cash & Equivalents data on file, last reported at $124.2 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 18.61% year-over-year to $124.2 million in Q4 2025; TTM through Dec 2025 was $124.2 million, a 18.61% decrease from a year earlier, with the FY2025 full-year figure at $124.2 million, down 18.61% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $124.2 million, down from $153.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for INBX reached as high as $277.9 million in Q4 2023 and fell as low as $124.2 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $191.8 million across 3 years, with a median of $191.4 million in 2024.
• Across the five-year window, Cash & Equivalents sank 45.09% in 2024 and retreated 17.76% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $277.9 million in 2023, then plunged by 45.09% to $152.6 million in 2024, then fell by 18.61% to $124.2 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $124.2 million in Q4 2025, $153.1 million in Q3 2025, and $186.6 million in Q2 2025.